Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Operating activities:
Net income (loss)	$ 41,980	$ 145,523	$ (11,016)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Deferred taxes	10,872	(126,613)	(1,828)
Depreciation of fixed assets and amortization of intangible assets	28,548	19,908	19,576
Amortization of debt issuance costs	2,754	2,156	1,707
Amortization of debt discount	23,152	18,254	13,746
(Gain) loss on disposal and impairment of fixed assets	(10)	22	1,010
Loss on early extinguishment of debt	0	8,071	0
Stock-based compensation	42,246	39,920	33,650
Changes in contingent consideration (after an acquisition)	(989)	5,204	16,672
(Gain) loss on investment (net of stock dividend) and other non-operating income, net	2,673	(1,618)	4,315
Changes in operating assets and liabilities (net of acquisitions):
Accounts receivable, net	(10,434)	(5,516)	(8,524)
Inventories, net	(4,467)	(6,353)	(8,026)
Prepaid expenses and other assets	1,142	(739)	(3,885)
Accounts payable	(10,262)	(3,312)	(1,822)
Accrued expenses and income taxes payable	5,451	(5,999)	22,041
Other liabilities	(229)	(2,467)	(6,726)
Payment of contingent consideration	(6,835)	(9,409)	(370)
Deferred revenue	125	0	0
Net cash provided by operating activities	125,717	77,032	70,520
Investing activities:
Acquisition of Flexion Therapeutics, Inc. (net of cash acquired)	420,042	0	0
Acquisition of MyoScience, Inc. (net of cash acquired)	0	0	(117,691)
Purchases of fixed assets	(45,866)	(37,801)	(10,159)
Purchases of available-for-sale investments	(611,488)	(546,516)	(318,484)
Sales of available-for-sale investments	1,068,736	307,870	319,468
Payment of contingent consideration	(4,000)	0	0
Sale of equity investment	9,057	0	0
Purchases of equity and debt investments	(17,187)	(1,160)	(1,622)
Net cash used in investing activities	(20,790)	(277,607)	(128,488)
Financing activities:
Proceeds from exercises of stock options	23,844	45,218	8,469
Proceeds from common stock issued under employee stock purchase plan	2,811	2,546	2,402
Proceeds from term loan B credit facility	363,750	0	0
Conversion premium on 2019 convertible senior notes	0	0	(233)
Payment of debt issuance and financing costs	(4,546)	(12,487)	0
Payment of contingent consideration	(5,165)	(5,591)	(6,630)
Net cash provided by financing activities	380,694	222,304	3,670
Net increase (decrease) in cash and cash equivalents	485,621	21,729	(54,298)
Cash and cash equivalents, beginning of year	99,957	78,228	132,526
Cash and cash equivalents, end of year	585,578	99,957	78,228
Supplemental cash flow information:
Cash paid for interest	6,996	7,205	8,199
Cash paid for income taxes, net of refunds	3,221	2,417	863
Non-cash investing and financing activities:
Fixed assets included in accounts payable and accrued liabilities	6,828	9,288	3,019
Net increase in contingent consideration liabilities	45,241	0	28,470
Convertible Senior Notes Due 2025
Financing activities:
Proceeds from debt component of the 2025 convertible senior notes	0	314,708	0
Proceeds from equity component of the 2025 convertible senior notes	0	87,792	0
Convertible Senior Notes 2019
Financing activities:
Repayment of convertible senior notes	0	0	(338)
Convertible Senior Notes Due 2022
Financing activities:
Repayment of convertible senior notes	0	(176,793)	0
Retirement of equity component of the 2022 convertible senior notes	$ 0	$ (33,089)	$ 0